Truist Financial
ALNY icon

Truist Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Truist Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
3,425
-4,276
-56% -$1.29M ﹤0.01% 1759
2026
Q1 		$2.55M Buy
7,701
+1,596
+26% +$543K ﹤0.01% 1179
2025
Q4 		$2.43M Sell
6,105
-361
-6% -$160K ﹤0.01% 1186
2025
Q3 		$2.95M Buy
6,466
+2,459
+61% +$1M ﹤0.01% 1141
2025
Q2 		$1.31M Buy
4,007
+383
+11% +$106K ﹤0.01% 1472
2025
Q1 		$979K Sell
3,624
-774
-18% -$199K ﹤0.01% 1531
2024
Q4 		$1.03M Buy
4,398
+2,539
+137% +$668K ﹤0.01% 1535
2024
Q3 		$511K Buy
1,859
+131
+8% +$34.1K ﹤0.01% 1848
2024
Q2 		$420K Sell
1,728
-623
-26% -$98.4K ﹤0.01% 2079
2024
Q1 		$351K Sell
2,351
-127
-5% -$21.2K ﹤0.01% 2209
2023
Q4 		$474K Buy
+2,478
New +$422K ﹤0.01% 2016
2023
Q2 		– Sell
-1,328
Closed -$266K – 2563
2023
Q1 		$266K Sell
1,328
-140
-10% -$29.4K ﹤0.01% 2287
2022
Q4 		$349K Buy
+1,468
New +$313K ﹤0.01% 2181
2022
Q3 		– Sell
-5,000
Closed -$729K – 2514
2022
Q2 		$729K Sell
5,000
-1,924
-28% -$273K ﹤0.01% 1697
2022
Q1 		$1.13M Sell
6,924
-671
-9% -$102K ﹤0.01% 1570
2021
Q4 		$1.29M Buy
7,595
+992
+15% +$184K ﹤0.01% 1507
2021
Q3 		$1.25M Buy
6,603
+40
+0.6% +$7.5K ﹤0.01% 1488
2021
Q2 		$1.11M Buy
6,563
+838
+15% +$123K ﹤0.01% 1576
2021
Q1 		$808K Buy
5,725
+3,972
+227% +$598K ﹤0.01% 1711
2020
Q4 		$228K Buy
1,753
+374
+27% +$49.9K ﹤0.01% 2321
2020
Q3 		$201K Sell
1,379
-390
-22% -$55.4K ﹤0.01% 2259
2020
Q2 		$262K Sell
1,769
-168
-9% -$22.6K ﹤0.01% 2040
2020
Q1 		$211K Sell
1,937
-201
-9% -$23.2K ﹤0.01% 2096
2019
Q4 		$245K Buy
+2,138
New +$213K ﹤0.01% 2264

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Truist Financial's ALNY Position: Q2 2026 in Review

Truist Financial reduced its Alnylam Pharmaceuticals (ALNY) stake by 56% in Q2 2026, selling an estimated $1.29M and leaving 3,425 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

Truist Financial first reported a position in ALNY in Q4 2019 and has held it in 24 quarters since. The position peaked at $2.95M in Q3 2025. 792 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Truist Financial held 3,425 shares of Alnylam Pharmaceuticals worth $1.03M as of Q2 2026.
  • Truist Financial sold 4,276 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.29M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1759 holding.
  • Truist Financial first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 24 quarters since.
  • Truist Financial's Alnylam Pharmaceuticals position peaked at $2.95M in Q3 2025.
  • 792 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.